Aisling Capital IV, LP - Jun 17, 2022 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Role
10%+ Owner
Signature
AISLING CAPITAL IV, LP, by Aisling Capital Partners IV, LP, its General Partner, by Aisling Capital Partners IV LLC, its General Partner, /s/ Andrew Schiff, Managing Member
Stock symbol
ELEV
Transactions as of
Jun 17, 2022
Transactions value $
$0
Form type
4
Date filed
6/22/2022, 06:43 PM
Previous filing
Jul 1, 2021
Next filing
Jun 21, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +15.6K $0.00 15.6K Jun 17, 2022 Common Stock 15.6K $1.31 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the total shares on the one year anniversary of the grant date, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F2 This stock option was granted to Steven Elms, an employee of Aisling Capital, in his capacity as a director of the Issuer. Pursuant to the policies of Aisling Capital, Mr. Elms does not have any right to any of the Issuer's securities issued as part of his service on the Board and Aisling Capital is entitled to receive all of the pecuniary interest in the securities issued.